Condition: Non-Small Cell Lung Cancer · Sponsor: Mabscale, LLC
BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin®. Study includes pharmacokinetics assessment.
This description comes directly from the study's public registry record.
Alexander Generalov, MD · +74997149289 · generalov.a@benerix.ru
Always discuss trial participation with your own doctor first.
| Arkhangelsk Clinical Oncological Dispensary | Arkhangelsk, Russia | Recruiting |
| State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary | Ivanovo, Russia | Recruiting |
| Kaluga Regional Clinical Oncology Dispensary | Kaluga, Russia | Recruiting |
| Regional clinical oncological dispensary n.a.Sigal | Kazan', Russia | Recruiting |
| Burdenko Main Military Clinical Hospital | Moscow, Russia | Recruiting |
| Hadassah Medical Moscow | Moscow, Russia | Withdrawn |
| National Medical Oncology Research Center n.a. N.N. Blokhina | Moscow, Russia | Not Yet Recruiting |
| Murmansk Regional Clinical Hospital | Murmansk, Russia | Recruiting |
| Nizhny Novgorod Regional Oncology Dispensary | Nizhny Novgorod, Russia | Recruiting |
| Novosibirsk oncologic dispensary | Novosibirsk, Russia | Recruiting |
| Omsk clinical oncologic dispensary | Omsk, Russia | Recruiting |
| Perm Edge Clinical Hospital | Perm, Russia | Not Yet Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05654454